{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:11:38Z","timestamp":1779084698096,"version":"3.51.4"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T00:00:00Z","timestamp":1539302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Mayo Clinic Robert M. and Billie Kelley Pirnie Translational PKD Research Center","award":["NIDDK P30 DK090728"],"award-info":[{"award-number":["NIDDK P30 DK090728"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>No treatment until now has directly targeted the mechanisms responsible for the development and growth of cysts in autosomal dominant polycystic kidney disease (ADPKD). Strong rationale and preclinical studies using in vitro and in vivo models justified the launching of two large phase 3 clinical trials of tolvaptan in early and later stages of ADPKD. Their design was based on preliminary studies informing on the pharmacokinetics, pharmacodynamics, short-term safety and self-reported tolerability in patients with ADPKD. Tolvaptan slowed kidney growth in the early stage and estimated glomerular filtration rate decline in early and later stages of the disease. All participants had the opportunity to enroll in open-label extension trials to ascertain long-term safety and efficacy. In a single-center analysis of long-term outcomes, the effect of tolvaptan was sustained and cumulative over time supporting a disease-modifying effect of tolvaptan in ADPKD. In the countries where tolvaptan has been approved by regulatory agencies, patients with rapidly progressive ADPKD should be informed about the option of treatment including possible benefits and risks. If a decision to initiate treatment is made, prescribing physicians should educate the patients on the prevention of aquaresis-related adverse events and should be vigilant in the surveillance and management of the potential tolvaptan hepatotoxicity. Other vasopressin V2 receptor antagonists, possibly without potential hepatotoxicity, alternative strategies targeting vasopressin and combination with other drugs able to enhance the efficacy or reduce the aquaresis associated with tolvaptan, deserve further study.<\/jats:p>","DOI":"10.1093\/ndt\/gfy297","type":"journal-article","created":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:07Z","timestamp":1535760007000},"page":"30-34","source":"Crossref","is-referenced-by-count":30,"title":["Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease"],"prefix":"10.1093","volume":"34","author":[{"given":"Vicente E","family":"Torres","sequence":"first","affiliation":[{"name":"Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,10,12]]},"reference":[{"key":"2019072508100490700_gfy297-B1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12020-012-9634-y","article-title":"The evolutionary origin of the vasopressin\/V2-type receptor\/aquaporin axis and the urine-concentrating mechanism","volume":"42","author":"Juul","year":"2012","journal-title":"Endocrine"},{"key":"2019072508100490700_gfy297-B2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/ki.1987.34","article-title":"Functional adaptation of thick ascending limb and internephron heterogeneity to urine concentration","volume":"31","author":"Trinh-Trang-Tan","year":"1987","journal-title":"Kidney Int"},{"key":"2019072508100490700_gfy297-B3","first-page":"457","article-title":"Histogenesis of the renal cysts in adult (autosomal dominant) polycystic kidney disease: a histochemical study","volume":"1","author":"Verani","year":"1988","journal-title":"Mod Pathol"},{"key":"2019072508100490700_gfy297-B4","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","article-title":"Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells","volume":"66","author":"Belibi","year":"2004","journal-title":"Kidney Int"},{"key":"2019072508100490700_gfy297-B5","doi-asserted-by":"crossref","first-page":"40419","DOI":"10.1074\/jbc.M405079200","article-title":"Calcium restriction allows cAMP activation of the B-Raf\/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype","volume":"279","author":"Yamaguchi","year":"2004","journal-title":"J Biol Chem"},{"key":"2019072508100490700_gfy297-B6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1681\/ASN.2005060645","article-title":"Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells","volume":"17","author":"Yamaguchi","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2019072508100490700_gfy297-B7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1210\/en.2008-0068","article-title":"Sustained elevated levels of circulating vasopressin selectively stimulate the proliferation of kidney tubular cells via the activation of V2 receptors","volume":"150","author":"Alonso","year":"2009","journal-title":"Endocrinology"},{"key":"2019072508100490700_gfy297-B8","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1248\/bpb.24.897","article-title":"Histopathological study of kidney abnormalities in an experimental SIADH rat model and its application to the evaluation of the pharmacologic profile of VP-343, a selective vasopressin V2 receptor antagonist","volume":"24","author":"Naito","year":"2001","journal-title":"Biol Pharm Bull"},{"key":"2019072508100490700_gfy297-B9","doi-asserted-by":"crossref","first-page":"F677","DOI":"10.1152\/ajprenal.00119.2017","article-title":"The regulatory 1alpha subunit of protein kinase A modulates renal cystogenesis","volume":"313","author":"Ye","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"2019072508100490700_gfy297-B10","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"key":"2019072508100490700_gfy297-B11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1681\/ASN.2013010077","article-title":"Adenylyl cyclase 6 deficiency ameliorates polycystic kidney disease","volume":"25","author":"Rees","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2019072508100490700_gfy297-B12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2017.08.005","article-title":"Adenylyl cyclase 5 deficiency reduces renal cyclic AMP and cyst growth in an orthologous mouse model of polycystic kidney disease","volume":"93","author":"Wang","year":"2018","journal-title":"Kidney Int"},{"key":"2019072508100490700_gfy297-B13","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1681\/ASN.2013040421","article-title":"Phosphodiesterase 1A modulates cystogenesis in zebrafish","volume":"25","author":"Sussman","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2019072508100490700_gfy297-B14","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.ajkd.2012.08.038","article-title":"Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort","volume":"61","author":"Boertien","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2019072508100490700_gfy297-B15","doi-asserted-by":"crossref","first-page":"F261","DOI":"10.1152\/ajprenal.00345.2014","article-title":"Effects of hydration in rats and mice with polycystic kidney disease","volume":"308","author":"Hopp","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"2019072508100490700_gfy297-B16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1124\/jpet.114.213256","article-title":"Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury","volume":"349","author":"Aihara","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"2019072508100490700_gfy297-B17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2019072508100490700_gfy297-B18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2019072508100490700_gfy297-B19","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/jcph.880","article-title":"Pharmacokinetics and pharmacodynamics of tolvaptan in autosomal dominant polycystic kidney disease: phase 2 trials for dose selection in the pivotal phase 3 trial","volume":"57","author":"Shoaf","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2019072508100490700_gfy297-B20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ki.2011.119","article-title":"Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease","volume":"80","author":"Irazabal","year":"2011","journal-title":"Kidney Int"},{"key":"2019072508100490700_gfy297-B21","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/ki.2013.285","article-title":"Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease","volume":"84","author":"Boertien","year":"2013","journal-title":"Kidney Int"},{"key":"2019072508100490700_gfy297-B22","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"2019072508100490700_gfy297-B23","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/ndt\/gfx079","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial","volume":"32","author":"Torres","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2019072508100490700_gfy297-B24","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"2019072508100490700_gfy297-B25","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2215\/CJN.01520218","article-title":"Long-term effect of tolvaptan on renal function in autosomal dominant polycystic kidney disease","volume":"13","author":"Edwards","year":"2018","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/34\/1\/30\/28999291\/gfy297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T01:34:43Z","timestamp":1569980083000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/34\/1\/30\/5127706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,12]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,10,12]]},"published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfy297","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,1]]},"published":{"date-parts":[[2018,10,12]]}}}